Novel Wheat Germ Cell-free Protein production Service

Added: Jan 18, 2017 9:09 am This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Ehime University to procure a Novel Wheat germ cell-free protein production and purification services for Malaria PfRh5 (1.04 mg) and PiRipr (1.6 mg) proteins.

The service will support Malaria vaccine development and functions of multiple Lab sections for NIH, NIAID, Laboratory of Malaria Immunology and Vaccinology Research (LMIV). The Novel Wheat germ cell-free protein production is performed using plant cells and not animals will be used. Place of service is Matsuyama, Japan.

The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one source available, to maintain continuity of established FDA approvals for the current Malaria vaccine development. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-RML-D-1831022) to Laura Grey at laura.grey@nih.gov, by 5:00 pm eastern standard time, Friday January 27th, 2017. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.